The estimated Net Worth of Mardi Dier is at least $7.2 Milhão dollars as of 14 October 2022. Ms Dier owns over 1,629 units of Ultragenyx Pharmaceutical stock worth over $3,756,929 and over the last 16 years she sold RARE stock worth over $3,228,710. In addition, she makes $216,346 as Exec. VP & CFO at Ultragenyx Pharmaceutical.
Ms has made over 26 trades of the Ultragenyx Pharmaceutical stock since 2008, according to the Form 4 filled with the SEC. Most recently she sold 1,629 units of RARE stock worth $65,421 on 14 October 2022.
The largest trade she's ever made was exercising 93,392 units of Ultragenyx Pharmaceutical stock on 27 June 2017 worth over $1,736,157. On average, Ms trades about 5,060 units every 77 days since 2008. As of 14 October 2022 she still owns at least 66,695 units of Ultragenyx Pharmaceutical stock.
You can see the complete history of Ms Dier stock trades at the bottom of the page.
Mardi C. Dier is the Exec. VP & CFO at Ultragenyx Pharmaceutical.
As the Exec. VP & CFO of Ultragenyx Pharmaceutical, the total compensation of Ms Dier at Ultragenyx Pharmaceutical is $216,346. There are 18 executives at Ultragenyx Pharmaceutical getting paid more, with Emil Kakkis having the highest compensation of $6,586,480.
Ms Dier is 57, she's been the Exec. VP & CFO of Ultragenyx Pharmaceutical since . There are 11 older and 13 younger executives at Ultragenyx Pharmaceutical. The oldest executive at Ultragenyx Pharmaceutical Inc. is William Aliski, 73, who is the Independent Director.
Mardi's mailing address filed with the SEC is C/O PRELUDE THERAPEUTICS INCORPORATED, 175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805.
Over the last 11 years, insiders at Ultragenyx Pharmaceutical have traded over $102,813,606 worth of Ultragenyx Pharmaceutical stock and bought 203,500 units worth $4,623,050 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Llc Fmr, eClay B Siegall. On average, Ultragenyx Pharmaceutical executives and independent directors trade stock every 17 days with the average trade being worth of $573,045. The most recent stock trade was executed by Emil D Kakkis on 3 September 2024, trading 20,000 units of RARE stock currently worth $1,117,000.
ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
Ultragenyx Pharmaceutical executives and other stock owners filed with the SEC include: